KR102466389B1 - 셀레노유기 화합물의 조성물 및 이의 사용 방법 - Google Patents

셀레노유기 화합물의 조성물 및 이의 사용 방법 Download PDF

Info

Publication number
KR102466389B1
KR102466389B1 KR1020217021039A KR20217021039A KR102466389B1 KR 102466389 B1 KR102466389 B1 KR 102466389B1 KR 1020217021039 A KR1020217021039 A KR 1020217021039A KR 20217021039 A KR20217021039 A KR 20217021039A KR 102466389 B1 KR102466389 B1 KR 102466389B1
Authority
KR
South Korea
Prior art keywords
compound
composition
cells
compounds
adenosyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217021039A
Other languages
English (en)
Korean (ko)
Other versions
KR20210104070A (ko
Inventor
로난 파워
지-지안 란
알렉산드로스 야니코우리스
Original Assignee
올텍 법인회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 올텍 법인회사 filed Critical 올텍 법인회사
Publication of KR20210104070A publication Critical patent/KR20210104070A/ko
Application granted granted Critical
Publication of KR102466389B1 publication Critical patent/KR102466389B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
KR1020217021039A 2014-03-14 2014-03-14 셀레노유기 화합물의 조성물 및 이의 사용 방법 Active KR102466389B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2014/029542 WO2015137983A1 (en) 2014-03-14 2014-03-14 Compositions of selenoorganic compounds and methods of use thereof
KR1020167024957A KR102448455B1 (ko) 2014-03-14 2014-03-14 셀레노유기 화합물의 조성물 및 이의 사용 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167024957A Division KR102448455B1 (ko) 2014-03-14 2014-03-14 셀레노유기 화합물의 조성물 및 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20210104070A KR20210104070A (ko) 2021-08-24
KR102466389B1 true KR102466389B1 (ko) 2022-11-11

Family

ID=54072241

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020217021039A Active KR102466389B1 (ko) 2014-03-14 2014-03-14 셀레노유기 화합물의 조성물 및 이의 사용 방법
KR1020167024957A Active KR102448455B1 (ko) 2014-03-14 2014-03-14 셀레노유기 화합물의 조성물 및 이의 사용 방법
KR1020160117539A Active KR102764247B1 (ko) 2014-03-14 2016-09-12 셀레노유기 화합물의 조성물 및 그의 사용 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020167024957A Active KR102448455B1 (ko) 2014-03-14 2014-03-14 셀레노유기 화합물의 조성물 및 이의 사용 방법
KR1020160117539A Active KR102764247B1 (ko) 2014-03-14 2016-09-12 셀레노유기 화합물의 조성물 및 그의 사용 방법

Country Status (16)

Country Link
US (3) US10201559B2 (cg-RX-API-DMAC7.html)
EP (1) EP3116511B1 (cg-RX-API-DMAC7.html)
JP (2) JP6313479B2 (cg-RX-API-DMAC7.html)
KR (3) KR102466389B1 (cg-RX-API-DMAC7.html)
CN (3) CN106456658A (cg-RX-API-DMAC7.html)
AU (4) AU2014386236B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016020233B1 (cg-RX-API-DMAC7.html)
CA (1) CA2940283C (cg-RX-API-DMAC7.html)
DK (2) DK3116511T3 (cg-RX-API-DMAC7.html)
HU (2) HUE051713T2 (cg-RX-API-DMAC7.html)
IL (1) IL247312A0 (cg-RX-API-DMAC7.html)
MX (2) MX2016011897A (cg-RX-API-DMAC7.html)
PE (1) PE20211069A1 (cg-RX-API-DMAC7.html)
PT (1) PT3116511T (cg-RX-API-DMAC7.html)
RU (2) RU2665135C2 (cg-RX-API-DMAC7.html)
WO (2) WO2015137983A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016011897A (es) * 2014-03-14 2017-04-27 Alltech Inc Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
US10639322B2 (en) 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
KR102054640B1 (ko) * 2015-09-24 2019-12-11 서울대학교산학협력단 아데노신 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AU2017234662A1 (en) * 2016-03-14 2018-10-04 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
CN120647702A (zh) 2017-05-19 2025-09-16 全技术公司 药剂、组合物及其相关方法
AU2018354090B2 (en) 2017-10-23 2024-10-24 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
WO2019093699A1 (ko) * 2017-11-09 2019-05-16 서울대학교 산학협력단 셀레노사마필린 a와 그 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
KR102083180B1 (ko) 2017-11-09 2020-03-02 서울대학교산학협력단 셀레노사마필린 a와 그 유도체, 이의 제조방법, 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
CN108484690B (zh) * 2018-05-16 2021-04-30 新乡拓新药业股份有限公司 一种1,2,3-三-O-乙酰基-5-脱氧-β-D-核糖的制备方法
EP3796976A4 (en) 2018-05-23 2022-03-30 Epitracker, Inc. COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO LONGEVITY AND QUALITY OF AGING
EP3908374A4 (en) * 2019-01-09 2022-12-28 Epitracker, Inc. COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
CN111543641A (zh) * 2020-04-27 2020-08-18 江苏惠利生物科技有限公司 一种提高l-硒-甲基硒代半胱氨酸稳定性以及生物利用率的方法
WO2022020658A1 (en) * 2020-07-23 2022-01-27 Purdue Research Foundation Notch signaling inhibitors for treating obesity and metabolic disorders
JP2024539823A (ja) 2021-11-03 2024-10-31 エピトラッカー インコーポレイテッド 老化の質および寿命に関係する状態の治療のためのペンタデカノイルカルニチン
JP2023076373A (ja) * 2021-11-22 2023-06-01 マルサンアイ株式会社 アミロイドβ凝集抑制剤とこれを含む医薬組成物および飲食品、ネプリライシン産生促進剤およびγ－セクレターゼ産生抑制剤
CN116333302B (zh) * 2023-03-31 2024-09-10 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用
US12285412B1 (en) 2024-12-27 2025-04-29 Imam Mohammad Ibn Saud Islamic University Organoselenium benzimidazole compounds for treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
JP4979866B2 (ja) 1999-09-08 2012-07-18 リガンド・ファーマシューティカルズ・インコーポレイテッド 肝臓に特異的なドラッグデリバリーのためのプロドラッグ
US6716825B2 (en) 1999-12-03 2004-04-06 The Regents Of The University Of California Phosphonate compounds
DE60117247D1 (de) 2000-03-31 2006-04-20 Purdue Research Foundation West Lafayette Phosphoramidat-prodrugs
TW200408645A (en) 2002-04-26 2004-06-01 Gilead Sciences Inc Non nucleoside reverse transcriptase inhibitors
AU2003235501A1 (en) 2002-05-13 2003-11-11 Metabasis Therapeutics, Inc. PMEA and PMPA cyclic producing synthesis
IL164809A0 (en) 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
EP1652519A1 (en) 2004-10-28 2006-05-03 Tamie Nasu Seleniferous composition for producing antioxidase in vivo
JP2006151965A (ja) * 2004-10-28 2006-06-15 Mi Tec:Kk セレン含有組成物及びその製法
WO2006071103A1 (en) * 2004-12-31 2006-07-06 Heonjoong Kang Organoselenium containing compounds and their use
US20060198906A1 (en) 2005-03-07 2006-09-07 Sami Labs Limited Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease
US20070077238A1 (en) 2005-10-04 2007-04-05 Teo Alex Y Production of organic and inorganic selenium compounds by lactic acid bacteria
CA2524551C (en) * 2005-10-14 2014-12-16 Alltech, Inc. Use of selenium yeasts in the treatment of alzheimer's disease
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
US20080004255A1 (en) 2005-10-14 2008-01-03 Alltech, Inc. Methods and compositions for altering cell function
AU2005227420B2 (en) * 2005-10-14 2013-05-09 Alltech, Inc. Method and compositions for altering cell function
CN101045048B (zh) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 线粒体营养素组合物的应用
WO2007127273A2 (en) 2006-04-24 2007-11-08 Alltech, Inc. Methods and compositions for altering cell function
EP2192905A4 (en) * 2007-08-29 2010-11-10 Adam Lubin METHOD FOR SELECTIVE THERAPY OF DISEASE
CN101835449A (zh) * 2007-08-31 2010-09-15 Dsmip资产有限公司 4-脒基苄胺用于美容和/或皮肤病学的用途
WO2009066299A2 (en) * 2007-11-23 2009-05-28 Rappaport Family Institute For Research Use of haptoglobin genotyping in diagnosis and treatment of cardiovascular disease
CN101289495A (zh) * 2008-05-23 2008-10-22 浙江大学 含硒五肽化合物及其应用
SG10201406651PA (en) * 2009-10-22 2014-11-27 Propanc Pty Ltd A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agent
JP5510302B2 (ja) * 2010-12-15 2014-06-04 トヨタ紡織株式会社 接続部材、その製造方法及び接続構造体
EP2694045B1 (en) * 2011-04-01 2019-10-30 Iasomai AB New combination comprising n-acetyl-l-cysteine and its use
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
NL2010222C2 (en) * 2013-02-01 2014-08-04 Conradus Ghosal Gho Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells.
CN105377271A (zh) * 2013-03-15 2016-03-02 全技术公司 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
MX2016011897A (es) 2014-03-14 2017-04-27 Alltech Inc Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
US20160000136A1 (en) * 2014-07-02 2016-01-07 Hamilton Beach Brands, Inc. Juice Extractor
US20160090397A1 (en) 2014-09-30 2016-03-31 Northeastern University Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Shona MacSheehy, et al., Analyst, 2002, 127, 223-229. (2002.01.03.)*

Also Published As

Publication number Publication date
KR20160125989A (ko) 2016-11-01
BR112016020233A2 (cg-RX-API-DMAC7.html) 2017-08-15
CN106822168B (zh) 2020-11-27
US10201559B2 (en) 2019-02-12
WO2015137983A1 (en) 2015-09-17
HUE051713T2 (hu) 2021-03-29
JP6313479B2 (ja) 2018-04-18
DK3116511T3 (da) 2020-11-23
PT3116511T (pt) 2020-11-19
PE20211069A1 (es) 2021-06-09
CA2940283C (en) 2021-03-30
AU2014386236A1 (en) 2016-09-01
CN106456658A (zh) 2017-02-22
KR102448455B1 (ko) 2022-09-28
RU2665135C2 (ru) 2018-08-28
RU2016133469A (ru) 2018-04-17
BR102016021058A2 (pt) 2017-05-30
HUE056172T2 (hu) 2022-01-28
US10201558B2 (en) 2019-02-12
AU2019246818B2 (en) 2021-02-25
WO2017048253A1 (en) 2017-03-23
KR20210104070A (ko) 2021-08-24
EP3116511A1 (en) 2017-01-18
US20160045533A1 (en) 2016-02-18
JP2017078056A (ja) 2017-04-27
DK3144001T3 (da) 2021-11-15
AU2022204588A1 (en) 2022-07-21
US20160082033A1 (en) 2016-03-24
KR102764247B1 (ko) 2025-02-07
RU2016136530A (ru) 2018-03-16
NZ723402A (en) 2024-11-29
BR112016020233B1 (pt) 2022-07-19
KR20170032862A (ko) 2017-03-23
CA2940283A1 (en) 2015-09-17
AU2014386236B2 (en) 2019-07-11
MX2016011898A (es) 2018-03-12
EP3116511A4 (en) 2017-10-18
CN106822168A (zh) 2017-06-13
RU2016136530A3 (cg-RX-API-DMAC7.html) 2019-11-25
CN113694074A (zh) 2021-11-26
JP7009053B2 (ja) 2022-01-25
AU2016222315B2 (en) 2022-08-04
US20160361338A1 (en) 2016-12-15
AU2019246818A1 (en) 2019-10-31
MX2016011897A (es) 2017-04-27
JP2017512828A (ja) 2017-05-25
AU2016222315A1 (en) 2017-03-30
RU2731383C2 (ru) 2020-09-02
IL247312A0 (en) 2016-09-29
EP3116511B1 (en) 2020-08-26
NZ723233A (en) 2020-10-30
US9642874B2 (en) 2017-05-09

Similar Documents

Publication Publication Date Title
KR102448455B1 (ko) 셀레노유기 화합물의 조성물 및 이의 사용 방법
CA2939592C (en) Compositions of selenoorganic compounds and methods of use thereof
HK40064580A (en) Compositions of selenoorganic compounds and methods of use thereof
HK1233497B (en) Compositions of selenoorganic compounds and methods of use thereof
NZ723233B2 (en) Compositions of selenoorganic compounds and methods of use thereof
HK1235284B (en) Compositions of selenoorganic compounds and methods of use thereof
BR102016021058B1 (pt) Uso de uma composição e método para modular o metabolismo de glicose em células do fígado
HK1235284A1 (en) Compositions of selenoorganic compounds and methods of use thereof
ES2357934B2 (es) Uso de un espirolido analogos y derivados para el tratamiento y/o la prevencion de patologias relacionadas con las proteinas tau y b-amiloide.

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210705

Application number text: 1020167024957

Filing date: 20160908

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210803

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211008

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220323

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211008

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220323

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20211208

Comment text: Amendment to Specification, etc.

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20220511

Patent event code: PE09021S02D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20220901

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220811

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220422

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220323

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20211208

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221108

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221109

End annual number: 3

Start annual number: 1

PG1601 Publication of registration